1. Home
  2. YPF vs UTHR Comparison

YPF vs UTHR Comparison

Compare YPF & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • YPF
  • UTHR
  • Stock Information
  • Founded
  • YPF 1977
  • UTHR 1996
  • Country
  • YPF Argentina
  • UTHR United States
  • Employees
  • YPF N/A
  • UTHR N/A
  • Industry
  • YPF Integrated oil Companies
  • UTHR Biotechnology: Pharmaceutical Preparations
  • Sector
  • YPF Energy
  • UTHR Health Care
  • Exchange
  • YPF Nasdaq
  • UTHR Nasdaq
  • Market Cap
  • YPF 16.8B
  • UTHR 14.4B
  • IPO Year
  • YPF 1993
  • UTHR 1999
  • Fundamental
  • Price
  • YPF $32.71
  • UTHR $301.42
  • Analyst Decision
  • YPF Buy
  • UTHR Buy
  • Analyst Count
  • YPF 7
  • UTHR 12
  • Target Price
  • YPF $40.73
  • UTHR $392.00
  • AVG Volume (30 Days)
  • YPF 2.2M
  • UTHR 418.7K
  • Earning Date
  • YPF 03-07-2025
  • UTHR 04-30-2025
  • Dividend Yield
  • YPF N/A
  • UTHR N/A
  • EPS Growth
  • YPF N/A
  • UTHR 18.86
  • EPS
  • YPF 5.14
  • UTHR 25.10
  • Revenue
  • YPF $17,356,963,208.00
  • UTHR $2,994,100,000.00
  • Revenue This Year
  • YPF $7.70
  • UTHR $11.45
  • Revenue Next Year
  • YPF N/A
  • UTHR $6.11
  • P/E Ratio
  • YPF $6.18
  • UTHR $12.01
  • Revenue Growth
  • YPF 226.28
  • UTHR 19.84
  • 52 Week Low
  • YPF $16.18
  • UTHR $260.41
  • 52 Week High
  • YPF $47.43
  • UTHR $417.82
  • Technical
  • Relative Strength Index (RSI)
  • YPF 54.45
  • UTHR 51.64
  • Support Level
  • YPF $29.33
  • UTHR $290.02
  • Resistance Level
  • YPF $32.55
  • UTHR $319.40
  • Average True Range (ATR)
  • YPF 1.36
  • UTHR 10.21
  • MACD
  • YPF 0.24
  • UTHR 2.36
  • Stochastic Oscillator
  • YPF 78.01
  • UTHR 45.61

About YPF YPF Sociedad Anonima

YPF SA is an Argentina-based integrated oil and gas company. It is engaged in operating a fully integrated oil and gas chain across the domestic upstream, downstream, and gas and power segments. The company's upstream operations consist of the exploration, development, and production of crude oil, natural gas, and LPG. Its downstream operations include the refining, marketing, transportation, and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels. The company generates maximum revenue from the downstream segment.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: